Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Sales (2018 - 2024)

Denali Therapeutics (DNLI) has disclosed Return on Sales for 7 consecutive years, with 331.22% as the latest value for Q2 2024.

  • Quarterly Return on Sales fell 33184.0% to 331.22% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 331.22% through Jun 2024, down 33084.0% year-over-year, with the annual reading at 0.44% for FY2023, 257.0% up from the prior year.
  • Return on Sales for Q2 2024 was 331.22% at Denali Therapeutics, down from 0.46% in the prior quarter.
  • The five-year high for Return on Sales was 5.48% in Q4 2020, with the low at 70041.0% in Q1 2021.
  • Average Return on Sales over 5 years is 4009.94%, with a median of 8.03% recorded in 2022.
  • The sharpest move saw Return on Sales tumbled -7002501bps in 2021, then soared 7003942bps in 2022.
  • Over 5 years, Return on Sales stood at 5.48% in 2020, then tumbled by -362bps to 14.32% in 2021, then soared by 31bps to 9.87% in 2022, then soared by 96bps to 0.44% in 2023, then crashed by -75286bps to 331.22% in 2024.
  • According to Business Quant data, Return on Sales over the past three periods came in at 331.22%, 0.46%, and 0.44% for Q2 2024, Q1 2024, and Q4 2023 respectively.